109 related articles for article (PubMed ID: 22771896)
1. Squamoproliferative lesions arising in the setting of BRAF inhibition.
Harvey NT; Millward M; Wood BA
Am J Dermatopathol; 2012 Dec; 34(8):822-6. PubMed ID: 22771896
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.
Anforth RM; Blumetti TC; Kefford RF; Sharma R; Scolyer RA; Kossard S; Long GV; Fernandez-Peñas P
Br J Dermatol; 2012 Nov; 167(5):1153-60. PubMed ID: 22804352
[TBL] [Abstract][Full Text] [Related]
3. Mutational Analysis of BRAF Inhibitor-Associated Squamoproliferative Lesions.
Clynick B; Tabone T; Fuller K; Erber W; Meehan K; Millward M; Wood BA; Harvey NT
J Mol Diagn; 2015 Nov; 17(6):644-51. PubMed ID: 26319365
[TBL] [Abstract][Full Text] [Related]
4. BRAF inhibitor induced verrucal keratosis.
Anforth R; Fernandez-Penas P
Am J Dermatopathol; 2014 Feb; 36(2):192. PubMed ID: 23435364
[No Abstract] [Full Text] [Related]
5. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
6. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
[TBL] [Abstract][Full Text] [Related]
7. Don't miss the base - keratoacanthoma-type squamous cell carcinoma with perineural invasion during BRAF inhibitor therapy for melanoma.
Schüürmann M; Pönitzsch I; Simon JC; Ziemer M
J Dtsch Dermatol Ges; 2015 Dec; 13(12):1279-81. PubMed ID: 26612802
[No Abstract] [Full Text] [Related]
8. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors.
Anforth R; Tembe V; Blumetti T; Fernandez-Peñas P
Pigment Cell Melanoma Res; 2012 Sep; 25(5):569-72. PubMed ID: 22726224
[TBL] [Abstract][Full Text] [Related]
9. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.
Chu EY; Wanat KA; Miller CJ; Amaravadi RK; Fecher LA; Brose MS; McGettigan S; Giles LR; Schuchter LM; Seykora JT; Rosenbach M
J Am Acad Dermatol; 2012 Dec; 67(6):1265-72. PubMed ID: 22609219
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous effects of BRAF inhibitor therapy: a case series.
Mattei PL; Alora-Palli MB; Kraft S; Lawrence DP; Flaherty KT; Kimball AB
Ann Oncol; 2013 Feb; 24(2):530-537. PubMed ID: 23035153
[TBL] [Abstract][Full Text] [Related]
11. No human virus sequences detected by next-generation sequencing in benign verrucous skin tumors occurring in BRAF-inhibitor-treated patients.
Ganzenmueller T; Hage E; Yakushko Y; Kluba J; Woltemate S; Schacht V; Schulz TF; Gutzmer R
Exp Dermatol; 2013 Nov; 22(11):725-9. PubMed ID: 24112647
[TBL] [Abstract][Full Text] [Related]
12. Clearance of BRAF inhibitor-associated keratoacanthomas by systemic retinoids.
Sachse MM; Wagner G
Br J Dermatol; 2014 Feb; 170(2):475-7. PubMed ID: 24117280
[No Abstract] [Full Text] [Related]
13. Rapidly developed BRAF inhibitor-induced verrucous keratosis.
Nakamura Y; Mori T; Takae Y; Tsutsumida A; Takahashi A; Namikawa K; Hirai I; Yamazaki N
J Dermatol; 2017 Nov; 44(11):e274-e275. PubMed ID: 28734005
[No Abstract] [Full Text] [Related]
14. Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma.
Ramani NS; Curry JL; Kapil J; Rapini RP; Tetzlaff MT; Prieto VG; Torres-Cabala CA
Am J Dermatopathol; 2015 Aug; 37(8):e96-9. PubMed ID: 25839886
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
Alloo A; Garibyan L; LeBoeuf N; Lin G; Werchniak A; Hodi FS; Flaherty KT; Lawrence DP; Lin JY
Arch Dermatol; 2012 Mar; 148(3):363-6. PubMed ID: 22431777
[TBL] [Abstract][Full Text] [Related]
16. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor.
Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
18. Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients.
Belum VR; Rosen AC; Jaimes N; Dranitsaris G; Pulitzer MP; Busam KJ; Marghoob AA; Carvajal RD; Chapman PB; Lacouture ME
Cancer; 2015 Jan; 121(1):60-8. PubMed ID: 25186461
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of BRAFi-induced hyperproliferative cutaneous conditions.
Ali M; Anforth R; Senetiner F; Carlos G; Fernandez-Penas P
Exp Dermatol; 2016 May; 25(5):394-5. PubMed ID: 26896751
[No Abstract] [Full Text] [Related]
20. Squamoproliferative skin lesion during braf inhibitors:one size does not fit all.
Mandalà M; Gianatti A; Massi D
J Eur Acad Dermatol Venereol; 2014 Mar; 28(3):389-91. PubMed ID: 23763655
[No Abstract] [Full Text] [Related]
[Next] [New Search]
